获取途径

作者

N. Wei B. Zhang Y. Wang X. H. He L. C. Xu G. D. Li Y. H. Wang G. Z. Wang H. Z. Huang W. T. Li

作者单位

Department of Interventional Radiology,Fudan University Shanghai Cancer Center,Shanghai,China Department of Interventional Medical, Peoples Hospital Xintai City,Taishan Medical University,Xintai,China

刊名

Clinical and Translational Oncology

页码

1-8

ISSN

1699-048X;1699-3055

关键词

Colorectal cancer Liver metastasis Raltitrexed Floxuridine Transcatheter arterial chemoembolization

分类号

616.992

摘要

Purpose To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine -based transarterial chemoembolization in patients with unresectable colorectal cancer liver metastasis . Methods We conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin , and 20 received TACE usin...更多

Purpose To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine -based transarterial chemoembolization in patients with unresectable colorectal cancer liver metastasis . Methods We conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin , and 20 received TACE using FUDR, oxaliplatin, and pirarubicin . The objective response rate , disease control rate , overall survival , progression-free survival , and adverse reactions were evaluated and compared between the two groups, and prognostic factors for OS were analyzed. Results The ORRs of the raltitrexed group and FUDR group were 67.2 and 45.0%, respectively , and the DCRs were 86.9 and 80.0%, respectively . The median OS was 14.0 months in the raltitrexed group and 13.0 months in the FUDR group . The median PFS was 2.1 months in the raltitrexed group and 2.4 months in the FUDR group . Univariate and multivariate analyses showed that the primary tumor site, Child–Pugh class, and combination with local ablation were independent significant factors affecting survival. There were no significant differences in adverse reactions between the two groups , and no treatment-related death occurred in either group. Conclusion TACE treatment based on raltitrexed or FUDR is an efficient and safe alternative choice for treating unresectable CRCLM.收起

学科

【SCI学科】ONCOLOGY

影响因子

2016年:2.353;2015年:2.075;2014年:2.077;2013年:1.6;2012年:1.276

文献类型

期刊

浏览量

14